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Abstract
Purpose Docetaxel is an important chemotherapeutic agent
used for the treatment of several cancer types. As radio-
labelled anticancer agents provide a potential means for
personalized treatment planning, docetaxel was labelled
with the positron emitter 11C. Non-invasive measurements
of [11C]docetaxel uptake in organs and tumours may
provide additional information on pharmacokinetics and
pharmacodynamics of the drug docetaxel. The purpose of
the present study was to determine the biodistribution and
radiation absorbed dose of [11C]docetaxel in humans.
Methods Biodistribution of [11C]docetaxel was measured in
seven patients (five men and two women) with solid
tumours using PET/CT. Venous blood samples were
collected to measure activity in blood and plasma. Regions
of interest (ROI) for various source organs were defined on
PET (high [11C]docetaxel uptake) or CT (low [11C]
docetaxel uptake). ROI data were used to generate time-
activity curves and to calculate percentage injected dose
and residence times. Radiation absorbed doses were
calculated according to the MIRD method using
OLINDA/EXM 1.0 software.
Results Gall bladder and liver demonstrated high [11C]
docetaxel uptake, whilst uptake in brain and normal lung
was low. The percentage injected dose at 1 h in the liver
was 47±9%. [11C]docetaxel was rapidly cleared from
plasma and no radiolabelled metabolites were detected.
[11C]docetaxel uptake in tumours was moderate and highly
variable between tumours.
Conclusion The effective dose of [11C]docetaxel was
4.7 µSv/MBq. As uptake in normal lung is low, [11C]
docetaxel may be a promising tracer for tumours in the
thoracic region.
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Introduction
Tumour resistance to chemotherapy remains a major
challenge, because it results in unnecessary toxicity and
costs and, most importantly, delay in initiating potentially
more effective treatment. In the last decade, there has been
growing interest in molecular imaging for tumour response
monitoring at an early stage during treatment. For example,
glucose metabolism as measured by the commonly used
positron emission tomography (PET) tracer 2-[18F]fluoro-2-
deoxy-D-glucose ([18F]FDG) has been accepted as a
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surrogate end-point for the evaluation of new drugs in
oncology [1]. However, [18F]FDG PET can only measure
tumour response after treatment has already been started by
comparing a response scan with the corresponding baseline
scan. Ideally, response to anticancer drugs should be
predicted before initiating therapy. Anticancer agents that
are labelled with a positron emitter may be promising
tracers for predicting treatment outcome before initiating
treatment [2]. A few studies have suggested that radio-
labelled anticancer agents may provide a unique means for
personalized treatment planning in cancer patients [2], but
more studies are needed to substantiate this concept. In
addition, radiolabelled anticancer agents may contribute to
drug development and the rational development of combi-
nation therapy strategies by exploring whether drug
pharmacokinetics can be modulated by other agents. The
anticancer drug docetaxel has been radiolabelled with 11C
[3–5]. Docetaxel belongs to the taxanes, one of the most
active classes of cytotoxic agents, and has been approved
for the treatment of several cancer types, including breast,
prostate and lung cancer [6]. Docetaxel acts by disrupting
the microtubular network which results in the inhibition of
mitosis in cells. In spite of this effective mechanism of
action in tumours, the efficacy of docetaxel treatment in
cancer patients is not optimal. Appropriate selection of
patients and addition of biomodulating agents may improve
efficacy of docetaxel therapy. PET using [11C]docetaxel
may be valuable, as it allows for measurement of docetaxel
uptake in tumours and for investigating effects of other
agents on this uptake. In preparation for kinetic studies in
cancer patients, the purpose of the present study was to
determine biodistribution and radiation absorbed doses of
[11C]docetaxel in humans.
Materials and methods
Patients
Patients with advanced solid tumours, due to undergo
chemotherapy, were eligible for this study. Inclusion criteria
were: 18 years of age or older, malignant lesion of at least
1.5 cm in diameter within the chest as measured by Response
Evaluation Criteria in Solid Tumors (RECIST) [7], life
expectancy of at least 12 weeks, Karnofsky performance
status scale>60%, platelets>100×109/l and haemoglobin>
6.0 mmol/l. Exclusion criteria included previous treatment
with taxanes, claustrophobia, pregnant or lactating patients,
patients having metal implants (e.g. pacemakers), use of
coumarin derivatives or inhibitors of platelet aggregation,
use of drugs that are inhibitors of or substrates for P-
glycoprotein (Pgp), concurrent treatment with experimental
drugs and participation in a clinical trial with any
investigational drug within 30 days prior to study entry.
The study was approved by the Medical Ethics Review
Committee of the VU University Medical Center. Five male
and two female patients with a mean age (± SD) of 63±
10 years and a mean body weight (± SD) of 78±15 kg (range:
66–94 kg) were included in the study. All patients were
diagnosed with metastatic cancer including non-small cell
lung cancer (NSCLC) (n=5), malignant pleural mesothelio-
ma (n=1) and prostate cancer (n=1). Prior to inclusion, each
patient signed a protocol-specific informed consent.
Synthesis of [11C]docetaxel
[11C]docetaxel was synthesized according to Good Manu-
facturing Practice (GMP) standards as described in detail
previously [4, 5]. For the preparation of the precursor, the drug
docetaxel was obtained from Green Plantchem Company Ltd.
(Hangzhou, China). Briefly, the 11C isotope was introduced in
the side chain by a [11C]tert-butoxycarbonylation of the free
amine of docetaxel, and [11C]docetaxel was produced with a
decay-corrected overall radiochemical yield of 10±1% prior to
purification. The mean specific activity at time of injection
was 7±5 GBq/μmol.
Scan protocol
Patients were asked to fast over midnight before scanning.
A light breakfast before 8.00 a.m. and water and tea were
allowed. Due to the fact that only sub-pharmacological
(tracer) doses of [11C]docetaxel were administered, no side
effects were expected. The Medical Ethics Review Com-
mittee, however, required that dexamethasone be given to
prevent potential allergic reactions. Two dosages of 4 mg
dexamethasone were given; one in the evening and the
other in the morning before [11C]docetaxel administration.
Whole-body scans were performed on a Gemini TF-64
PET/CT scanner (Philips Medical Systems, Best, The
Netherlands) [8]. Each patient was positioned on the
scanner bed using elastic body-restraining bandages to
minimize body movement during the scans. Following a
50 mAs low-dose CT (LD-CT) scan, a mean (± SD) single
bolus of 178±79 MBq [11C]docetaxel (dissolved in a
maximum volume of 12 ml saline) was injected intrave-
nously and four serial whole-body PET scans from head to
mid-thigh were acquired over a 1-h period with progressive
increase of scan durations per bed position of 0.5, 1, 1.5
and 2 min, respectively. The axial field of view of the
scanner is 18 cm and a 50% overlap between bed positions
is applied in whole-body scans, resulting in an average of
11 bed positions per scan. Resulting mean durations of the
four consecutive whole-body PET scans were 6.9±1.2,
12.6±2.3, 18.3±3.3 and 24.0±4.3 min, respectively. One
patient was able and willing to undergo a fifth whole-body
Eur J Nucl Med Mol Imaging (2010) 37:1950–1958 1951
scan with duration of 2.5 min per bed position. Data was
normalized and all appropriate corrections were applied for
dead time, randoms, scatter, attenuation and scanner
calibration, and whole-body scans were corrected for decay
relative to the start of each scan. Images were reconstructed
using time-of-flight ordered subsets expectation maximiza-
tion (TF-OSEM).
Analysis of blood samples
After each whole-body scan, a venous blood sample (7 ml)
was collected for measuring blood and plasma concen-
trations as well as radiolabelled metabolites. To avoid
contamination of activity remaining in the catheter, 3–5 ml
blood was withdrawn prior to each sample and the line was
flushed with 2 ml saline after sampling, as described
previously [9]. A cross-calibrated gamma counter was used
to determine activity concentrations and plasma to whole
blood ratios. The presence of radiolabelled metabolites in
plasma was assessed using solid phase extraction (SPE)
combined with high-performance liquid chromatography
(HPLC) using offline detection.
Region of interest definition
PET and LD-CT images were converted to ECAT 7 format
and regions of interest (ROIs) were drawn using CAPP
software (CTI/Siemens, Knoxville, TN, USA) to obtain
mean activity concentration in each region at each of the
four time points. For organs with activity concentrations
clearly exceeding background levels [liver, gall bladder,
upper large intestine (ULI), urinary bladder, heart wall,
bone marrow in vertebrae], ROIs were defined on the PET
scan with the highest tracer uptake (Fig. 1) using a 50%
isocontour. For organs with lower tracer uptake (brain,
lung, spleen, kidney) that could easily be identified on the
LD-CT scan, ROIs were drawn manually on the LD-CT
scan and subsequently copied to the PET scans (Fig. 2). For
each patient, a ROI of one tumour of at least 1.5 cm in
diameter that could easily be identified on the LD-CT scan
was determined. All ROIs were projected onto all scans. As
the volume of the urinary bladder increased during
scanning, bladder ROIs were separately drawn on each
PET image except for the first image. The bladder ROI of
the second image was projected onto the first PET scan.
Calculation of [11C]docetaxel uptake
ROIs were used to generate time-activity curves (TAC) for
each source organ. The time of measurement of each
individual organ in each scan was calculated based on the
organ position in the whole-body image and the total
duration of that scan. All organ TACs were then corrected
for decay relative to the time of injection of the tracer. To
assess biodistribution, the mean standardized uptake value
(SUV) normalized to body weight and the percentage
injected dose (%ID) in each organ were calculated at each
time point. For organs with ROIs covering less then the
entire organ (ULI, myocardial wall, red marrow), the
percentage of injected activity per cm3 was multiplied with
the organ volumes of the adult male reference phantom,
scaled with the ratio of the patient’s weight and the
reference man weight [10, 11]. Since bones not containing
active marrow were not visible in the images, all activity in
vertebrae ROIs was assumed to be in red marrow. For
tumours, the maximum SUV (SUVmax) was calculated.
Residence time and absorbed dose calculations
For each organ, TACs were uncorrected for decay and
residence times were computed as the trapezoidal sum of
the TAC with the assumption that, after the last time point,
activity decreased only by physical decay (i.e. no biological
clearance after the last time point). Residence time for the
remainder of the body was calculated as the total body
residence time without voiding (one divided by the decay
constant) minus the sum of the residence times of all
defined organs. Residence times for each patient were
Fig. 1 For organs with activity clearly exceeding background (e.g.
liver) ROIs were defined on the PET scan with the highest uptake.
PET/CT fusion image (a) and PET image (b) demonstrate high [11C]
docetaxel uptake in liver. The liver ROI as determined on the PET
image is presented in green (b)
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entered into the OLINDA/EXM 1.0 software package [12]
to compute absorbed doses using the adult male reference
phantom. Since the small intestine (SI) was difficult to
delineate in both PET and LD-CT images due to the
vicinity to the liver and the poor contrast of the LD-CT
images, the ICRP 30 GI [13] tract model was used to
estimate residence times in SI and lower large intestine
(LLI) based on those found for ULI. According to this
model, ratios of SI to ULI and LLI to ULI residence times
are 8.45 and 0.039, respectively, for 11C-labelled tracers
[12]. OLINDA/EXM 1.0 provides effective dose values
according to ICRP 60 [14] and does not provide effective
dose values according to the latest definition (ICRP 103,
[15]). Therefore, effective doses according to ICRP 103
were calculated manually using target organ doses as
reported by OLINDA/EXM 1.0 and ICRP 103 weighting
factors. Since not all target organs are included in
OLINDA/EXM 1.0 (skin, salivary glands, oesophagus),
the sum of weighting factors was 0.94 and effective dose
values were divided by 0.94 [16].
Results
Biodistribution
Figure 3 shows the typical biodistribution of [11C]docetaxel
over time, as obtained from the four sequential PET
acquisitions over about 1 h. Liver, gall bladder, intestine
and urinary bladder were visually identified as organs with
relatively high activity, whilst [11C]docetaxel uptake in
brain and normal lung was low. Between the third and
fourth PET scans, [11C]docetaxel uptake in gall bladder and
intestine was still increasing. Figure 4 shows TACs for
various organs [%ID versus time post-injection (p.i.)].
Percentage ID at 1 h p.i. was highest in liver (47±9%) and
gall bladder (7.2±3.6%), with 35% of all disintegrations
occurring in the liver. The highest peak activity concentrations
were measured in gall bladder (SUVmean 96±49), liver
(SUVmean 24±3) and ULI (SUVmean 9±6), whereas concen-
trations were smallest in brain (SUVmean 0.05±0.03) and
lung (SUVmean 0.7±0.2).
Fig. 2 For organs with lower tracer uptake (e.g. lung), ROIs were
drawn on the LD-CT scan and subsequently copied onto the PET
scans. PET/CT fusion image (a) and PET image demonstrate low
[11C]docetaxel uptake in lungs. The lung ROIs were drawn on the CT
image (b) and projected onto the PET image (c). The lung ROIs as
determined on the LD-CT scan are presented in green (b, c)
Fig. 3 Maximum intensity pro-
jections of the biodistribution of
[11C]docetaxel in a 71-year-old
male patient with metastatic
malignant pleural mesothelioma.
The four successive whole-body
PET scans (0–6, 8–19, 23–39
and 42–63 min p.i.) demonstrate
high liver uptake at all time
points and low uptake in brain
and normal lung. On the fourth
scan, [11C]docetaxel uptake is
observed in intestine
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Blood clearance
[11C]docetaxel was rapidly cleared from the blood pool and
within 30 min %ID/ml was less than 0.001, as shown in
Fig. 5. After the first PET scan, plasma values were higher
than those of whole blood, but after the second scan and
onwards whole blood values were higher. No radiolabelled
metabolites were detected in plasma, with the HPLC
chromatogram showing a single peak due to [11C]docetaxel
itself. Recovery of radioactivity in the HPLC analysis was
94±5%.
Safety
Patients did not report any side effect or discomfort after
the [11C]docetaxel injection and during the imaging
procedure.
Radiation dosimetry
Table 1 summarizes average organ residence times calcu-
lated from the whole-body images of the seven patients.
Organ absorbed dose estimates are displayed in Table 2.
Estimated radiation absorbed doses were highest in liver
and gall bladder wall at 35.2±6.6 and 34.6±9.9 µGy/MBq,
respectively. Based on these results, the mean effective dose
for [11C]docetaxel was estimated at 4.7±0.2 µSv/MBq.
Tumour uptake
[11C]docetaxel uptake was observed in tumours. Figure 6
shows a patient with [11C]docetaxel uptake in a mediastinal
metastasis of a malignant pleural mesothelioma. In each
patient, one tumour was selected for further analysis,
consisting of primary NSCLC (n=3), mediastinal lymph
Fig. 4 Decay-corrected TACs of [11C]docetaxel (%ID versus time p.i.) (n=7) in a liver, b ULI and gall bladder, c brain, lung, heart contents and
myocardial wall, and d urinary bladder, spleen, kidney and red marrow. Vertical bars indicate standard deviation
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node metastasis of NSCLC (n=1), supraclavicular lymph
node metastasis of NSCLC (n=1), mediastinal lymph node
metastasis of malignant pleural mesothelioma (n=1) and
lung metastasis of prostate cancer (n=1).The TACs for
these seven tumours are shown in Fig. 7. The highest
measured SUVmax was 5.1.
Discussion
In the present study, the biodistribution of [11C]docetaxel
was measured in seven patients with metastatic solid
tumours using whole-body PET/CT scans, and radiation
absorbed doses were estimated. The LD-CT scan was of additional value to identify organs with low [11C]docetaxel
uptake. Uptake of [11C]docetaxel appeared to be highest in
gall bladder and liver, whilst uptake in normal lung and
brain was very low. Furthermore, [11C]docetaxel uptake in
tumours was moderate and highly variable between
different tumours. The results of the present study showed
promising biodistribution and radiation dosimetry of [11C]
docetaxel. For a typical administration of 370 MBq [11C]
docetaxel, the estimated dose is 1.7 mSv, which is within
the 1–10 mSv range of effective doses that are acceptable
for volunteers in biomedical research [17]. The tracer was
rapidly cleared from the blood pool which resulted in
images of high quality and reliable statistics for quantifica-
tion. The main route of elimination of the tracer was the
hepatobiliary pathway which contributed to a relatively
high radiation burden to gall bladder and liver. During the
successive PET scans, extensive hepatic uptake and
subsequent excretion into gall bladder and intestine were
observed (Fig. 3). The SUVmean of [
11C]docetaxel was
highest in gall bladder, which is also the dose-limiting organ
for [11C]docetaxel. For an administration of 370 MBq, the
Fig. 5 Decay-corrected TACs of [11C]docetaxel (%ID/ml versus time
p.i.) in plasma and whole blood
Table 2 Radiation absorbed dose estimates for [11C]docetaxel
Target organ µGy/MBq (mean±SD)
Adrenals 4.1±0.2
Brain 0.5±0.1
Breast 1.6±0.1
Gall bladder wall 34.6±9.9
Lower large intestine wall 2.1±0.3
Small intestine 9.5±3.8
Stomach 2.6±0.1
Upper large intestine wall 5.1±1.2
Heart wall 6.0±1.0
Kidney 10.7±1.5
Liver 35.2±6.6
Lung 4.1±1.0
Muscle 1.9±0.2
Ovary 2.4±0.3
Pancreas 4.0±0.1
Red marrow 3.2±0.2
Bone surface 3.1±0.3
Skin 1.3±0.2
Spleen 7.4±2.3
Testis 1.3±0.3
Thymus 1.8±0.2
Thyroid 1.4±0.3
Urinary bladder wall 3.1±1.1
Uterus 2.3±0.3
Total body 2.9±0.0
Effective dose (µSv/MBq) 4.7±0.2
Table 1 Average (± SD) organ residence times for [11C]docetaxel
uptake (n=7)
Organ Organ residence time (h)
Brain 0.0008±0.0003
Gall bladder 0.0124±0.0045
Small intestine 0.0243±0.0133
Upper large intestine 0.0029±0.0016
Lower large intestine 0.0001±0.0001
Heart contents 0.0046±0.0016
Heart wall 0.0032±0.0006
Kidney 0.0085±0.0016
Liver 0.2047±0.0401
Lung 0.0095±0.0038
Red marrow 0.0128±0.0018
Spleen 0.0041±0.0015
Urinary bladder 0.0023±0.0015
Remainder of body 0.2002±0.0421
Eur J Nucl Med Mol Imaging (2010) 37:1950–1958 1955
absorbed dose to the gall bladder wall is 12.8±3.7 mGy.
This equals 26% of the maximum allowed dose of 50 mGy
to a single organ for a single administration to an adult
research subject [18]. The high liver uptake of [11C]
docetaxel suggests extensive metabolism of the tracer. The
fact that no radioactive metabolites were measured in plasma
shows that if radioactive metabolites are produced, none of
these enter the bloodstream during the course of the PET
scan and, consequently, none are transported to tumours. In
fact, radioactivity was nearly completely cleared from
plasma within the first 20 min. This does not rule out the
presence of re-circulating non-radiolabelled metabolites in
plasma, as has been observed in earlier studies with
therapeutic doses of cold docetaxel [19].
Uptake in all organs except gall bladder and ULI reached a
plateau within 10 min after injection, after which %ID
remained nearly constant during the rest of the scan. Therefore,
further clearance according to physical decay only appears to
be a valid assumption. During the fourth PET scan (∼60 min
after injection), uptake in gall bladder and ULI was still
increasing, indicating that the absorbed dose of [11C]docetaxel
in gall bladder and intestine might be underestimated. In the
patient who underwent a fifth whole-body scan, however, gall
bladder and ULI uptake decreased rapidly during the last
scan. Inclusion of this fifth scan resulted in a decreased
effective dose (4.0 vs 4.1 mSv/MBq), although giving a small
increase in absorbed dose to the gall bladder (Fig. 8). This
indicates that exponential extrapolation according to physical
decay after the fourth measurement yields conservative
effective dose values. The use of more and faster whole-
body scans within the first hour after injection, as has been
published for similar studies with other tracers [20, 21],
would not have led to major differences in the results because
of the near constant uptake in most organs.
Fig. 7 Decay-corrected TACs of [11C]docetaxel for seven different
tumours (SUVmax versus time p.i.) including mediastinal metastasis of
malignant pleural mesothelioma (a), metastasis of NSCLC (b, d),
primary tumour of NSCLC (c, e, f) and lung metastasis of prostate
cancer (g)
Fig. 6 PET/CT images of [11C]docetaxel in a 71-year-old male patient with metastatic malignant pleural mesothelioma. Mediastinal metastasis
(arrow) on CT scan (a) with [11C]docetaxel uptake on PET scan (b) and on PET/CT fusion image (c)
Fig. 8 Total activity (non-decay-corrected) in gall bladder in a single
patient who underwent an additional fifth whole-body scan. Solid lines
show the interpolated data from which the trapezoidal integral was
computed, assuming physical decay after the fourth whole-body scan,
whereas dashed lines show the integral after inclusion of the fifth
whole-body scan
1956 Eur J Nucl Med Mol Imaging (2010) 37:1950–1958
As most anticancer agents are eliminated by liver,
extensive hepatic clearance and subsequent excretion into
the gall bladder and intestine may also be expected for
other radiolabelled anticancer drugs. Due to the resulting
high background and low contrast in the abdomen, the
value of these radiolabelled anticancer drugs for tumours in
the abdominal and pelvic region may be limited.
Paclitaxel, another taxane, has been radiolabelled with
18F [22, 23]. To our knowledge, the radiation absorbed dose
of [18F]fluoropaclitaxel has not been reported yet. Limited
data on the biodistribution of [18F]fluoropaclitaxel in
humans [24], however, appeared to be comparable with
the present biodistribution data of [11C]docetaxel. Follow-
ing intravenous administration of [18F]fluoropaclitaxel,
PET scans were performed in three healthy volunteers.
High [18F]fluoropaclitaxel uptake was observed in liver,
gall bladder and intestine, whilst uptake in brain and lung
appeared to be low. Seventy-five minutes after injection,
[18F]fluoropaclitaxel had been cleared from liver and
subsequently excreted into intestine. When comparing
biodistribution and pharmacokinetics of [18F]fluoropacli-
taxel and [11C]docetaxel, it is important to realize that the
chemical structure of [11C]docetaxel is identical to that of
clinically used, non-labelled docetaxel, whilst [18F]fluoro-
paclitaxel is not identical to paclitaxel itself [22]. Introduc-
tion of a fluoride atom into the paclitaxel molecule
effectively creates a different chemical structure and may
result in a molecule with different pharmacokinetic and
pharmacodynamic characteristics as compared to the
paclitaxel molecule that is usually administered for the
treatment of patients.
The present biodistribution results for [11C]docetaxel are
in line with three clinical observations in cancer patients
who are treated with docetaxel. First, the extensive hepatic
clearance of [11C]docetaxel indicates that caution is
warranted when treating patients with liver dysfunction.
Indeed, in patients with clinical chemistry findings sugges-
tive of mild to moderate liver function impairment [SGOT
and/or SGPT > 1.5 × upper limit of normal (ULN),
concomitant with alkaline phosphatase > 2.5 × ULN], total
body clearance of the drug docetaxel is known to be
lowered significantly. Second, [11C]docetaxel uptake in
bone marrow may mirror neutropenia, which was the dose-
limiting toxicity in previous phase I clinical trials of
docetaxel [25]. Third, [11C]docetaxel uptake in brain was
low. The blood-brain barrier is likely to be the major cause
of this poor uptake. An important component of the blood-
brain barrier is Pgp [26, 27], which acts as a drug efflux
pump and for which docetaxel is a substrate [28]. This is
reflected by the limited efficacy of systemic treatment with
docetaxel for tumours or metastases in the brain [29]. In
addition, Pgp-mediated efflux in the blood-testis barrier is
known to maintain low drug concentrations in the testis
[30]. Indeed, visual inspection of the [11C]docetaxel PET
images did not reveal any [11C]docetaxel uptake in the
testicular region, indicating that [11C]docetaxel uptake in
the testis is probably low.
Although not the primary aim of this study, [11C]
docetaxel uptake was also measured in tumours. Tumour
uptake was highly variable, which may mirror differential
sensitivity of tumours to docetaxel treatment. Studies with
other radiolabelled anticancer agents such as [18F]5-
fluorouracil (FU) and [18F]fluorotamoxifen [2] have shown
that higher uptake of these radiolabelled agents in tumours
appeared to be related to better tumour response. Radio-
labelled anticancer agents could potentially predict treatment
outcome and may contribute to individualized treatment
planning. As patients in the present study were not scheduled
to undergo docetaxel treatment, further studies are warranted
to investigate whether tumour uptake of [11C]docetaxel is
predictive of outcome of docetaxel therapy. As background
uptake of [11C]docetaxel in the chest is low, it may be a
useful tracer to predict docetaxel efficacy for tumours in the
thoracic region, such as lung and breast cancer.
Conclusion
The highest uptake of [11C]docetaxel was measured in gall
bladder and liver, whilst uptake in brain and lung was very
low. Administration of [11C]docetaxel was safe with a mean
effective dose of 4.7 µSv/MBq. [11C]docetaxel uptake in
tumours was moderate and highly variable between
different tumours.
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